Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Jingwen Wang, Bo Jia et al.|Journal of Hematology & Oncology|2017Cited by 256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Peng Liu, Wenqi Jiang et al.|The Lancet Haematology|2019Cited by 248
Fluidic Multivalent Membrane Nanointerface Enables Synergetic Enrichment of Circulating Tumor Cells with High Efficiency and ViabilityLingling Wu, Chaoyong Yang, Hong‐Ming Ding et al.|Journal of the American Chemical Society|2020Cited by 170
Point Mutation of the Proteasome β5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia LineShuqing Lü, Jianmin Wang, Jianmin Yang et al.|Journal of Pharmacology and Experimental Therapeutics|2008Cited by 107
Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat lineShuqing Lü, Jianmin Wang, Zhilong Chen et al.|Experimental Hematology|2008Cited by 89